

RealRate

PHARMACEUTICAL 2021

Cellectar Biosciences Inc. Rank 47 of 402







RealRate

Cellectar Biosciences Inc. Rank 47 of 402

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 206% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	57,940
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,563
Liabilities, Non-Current	302
Other Assets	364
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	196
Other Revenues	0
Property and Equipment	356
Research and Development	10,141
Selling, General and Administrative Expense	5,150

Output Variable	Value in 1000 USD
Assets	58,659
Liabilities	3,865
Expenses	15,290
Revenues	0
Stockholders Equity	54,795
Net Income	-15,094
Comprehensive Net Income	-15,094
Economic Capital Ratio	253%

